Findings

What do systematic reviews say?

8 questions · 13 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 30.8%GRADE not reported 2 · 15.4%Very low 6 · 46.2%Low 1 · 7.7%Moderate 0 · 0%High 0 · 0%

Methotrexate and azathioprine vs methotrexate (plus leucovorin)

Muscle strength · people with inclusion body myositis

2 findings from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
GRADE not reported
Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methotrexate and azathioprine vs methotrexate (plus leucovorin)

Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methotrexate and azathioprine vs methotrexate (plus leucovorin)

Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methotrexate and azathioprine vs methotrexate (plus leucovorin)

Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Methotrexate and azathioprine vs methotrexate (plus leucovorin)

Significant adverse events · people with inclusion body myositis

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
GRADE not reported

Methotrexate vs 6‐MP or azathioprine

Adverse events (Ardizzone 2003) · adult patients with refractory Crohn's disease

It is very uncertain whether methotrexate changes adverse events (Ardizzone 2003) compared with 6‐MP or azathioprine (very low certainty).

1 finding from 1 review

Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only
RR 2.43 [1.21, 4.89]
1 study · 54 participants
Very low

Methotrexate vs 6‐MP or azathioprine

Withdrawals due to adverse events · adult patients with refractory Crohn's disease

It is very uncertain whether methotrexate changes withdrawal due to adverse event (Oren 1997) compared with 6‐MP or azathioprine (very low certainty).

3 findings from 1 review

Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only
RR 1.23 [0.08, 18.74]
1 study · 58 participants
Very low
Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only
RR 2.13 [0.22, 21.17]
1 study · 31 participants
Very low
Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only
RR 1 [0.22, 4.52]
1 study · 54 participants
Very low

Methotrexate vs 6‐MP or azathioprine

Failure to enter remission or possible remission at 16 weeks (Arora 1999) · adult patients with refractory Crohn's disease

Methotrexate showed no clear difference in failure to enter remission or possible remission at 24‐36 weeks… compared with 6‐MP or azathioprine (low certainty).

3 findings from 1 review

Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only
RR 1.36 [0.97, 1.92]
1 study · 58 participants
Low
Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only
RR 3.2 [0.37, 27.49]
1 study · 31 participants
Very low
Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes only
RR 1.2 [0.63, 2.29]
1 study · 54 participants
Very low